PMID- 9212355
OWN - NLM
STAT- MEDLINE
DCOM- 19970902
LR  - 20180216
IS  - 0301-0147 (Print)
IS  - 0301-0147 (Linking)
VI  - 27
IP  - 2
DP  - 1997 Mar-Apr
TI  - Efficacy and safety of low molecular weight heparin, unfractionated heparin and 
      warfarin for thrombo-embolism prophylaxis in orthopaedic surgery: a meta-analysis 
      of randomised clinical trials.
PG  - 75-84
AB  - The efficacy and safety of low molecular weight heparin (LMWH), unfractionated 
      heparin (UFH) and warfarin for prophylaxis of thrombo-embolism in orthopaedic 
      surgery were compared using meta-analysis techniques. Twenty-two studies were 
      included, 2 of which compared LMWH to warfarin. The mean probabilities to develop 
      deep-vein thrombosis (DVT), pulmonary embolism and major and minor bleeding using 
      UFH were: 0.21 (95% confidence interval, CI: 0.18-0.24); 0.01 (95% CI: 
      0.01-0.02); 0.05 (95% CI: 0.03-0.07), and 0.19 (95% CI: 0.17-0.22), respectively. 
      The relative risk (RR) of DVT for LMWH vs. UFH was 0.76 (95% CI: 0.60-0.91), p < 
      0.05 and for LMWH vs. warfarin 0.78 (95% CI: 0.69-0.87), p < 0.05. The RR of 
      minor bleeding for LMWH vs. UFH was 0.76 (95% CI: 0.64-0.92), p < 0.05. The RR of 
      minor bleeding for LMWH vs. warfarin was 3.28 (95% CI: 2.21-4.70), p < 0.05. 
      CONCLUSION: in orthopaedic surgery, LMWH is significantly superior to both UFH 
      and warfarin in the prevention of DVT and results in significantly less minor 
      bleeding complications when compared to UFH, but significantly more minor 
      bleeding when compared to warfarin.
FAU - Palmer, A J
AU  - Palmer AJ
AD  - Institute for Medical Informatics and Biostatistics, Riehen, Switzerland.
FAU - Koppenhagen, K
AU  - Koppenhagen K
FAU - Kirchhof, B
AU  - Kirchhof B
FAU - Weber, U
AU  - Weber U
FAU - Bergemann, R
AU  - Bergemann R
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - Switzerland
TA  - Haemostasis
JT  - Haemostasis
JID - 0371574
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 5Q7ZVV76EI (Warfarin)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Hemorrhage/chemically induced
MH  - Heparin/adverse effects/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/adverse effects/*therapeutic use
MH  - Humans
MH  - *Orthopedics
MH  - Postoperative Complications/*prevention & control
MH  - Randomized Controlled Trials as Topic
MH  - Thromboembolism/*prevention & control
MH  - Warfarin/adverse effects/*therapeutic use
EDAT- 1997/03/01 00:00
MHDA- 1997/03/01 00:01
CRDT- 1997/03/01 00:00
PHST- 1997/03/01 00:00 [pubmed]
PHST- 1997/03/01 00:01 [medline]
PHST- 1997/03/01 00:00 [entrez]
AID - 10.1159/000217437 [doi]
PST - ppublish
SO  - Haemostasis. 1997 Mar-Apr;27(2):75-84. doi: 10.1159/000217437.